Assembly Biosciences, Inc. Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs
Assembly Biosciences, Inc. (ASMB) had Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs of $341.00 thousand as of 2009-12-31, per its 10-K filed 2014-03-31.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Deferred Expense
us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts · last filed 2014-03-31
- 2009-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $341.00K.
- 2007-10-09: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $341.00K.
| Period end | Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs |
|---|---|
| 2009-12-31 | $341.00K 10-K · filed 2014-03-31 |
| 2007-10-09 | $341.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |